Home >> WZ811
Related Products
WZ811 Competitive CXCR4 antagonist,highly potent

Catalog No.B1466
Size Price Stock Qty
10mg
$81.00
In stock
50mg
$226.00
In stock
100mg
$316.00
In stock
500mg
$768.00
In stock
1g
$1,268.00
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

      

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & MSDS

View current batch:

Chemical structure

WZ811

Biological Activity

Description WZ811 is a highly potent competitive antagonist of CXCR4 with an EC50 value of 0.3 nM.
Targets CXCR4          
IC50 0.3 nM(EC50)          

WZ811 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

WZ811 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Chemical Properties

Cas No. 55778-02-4 SDF Download SDF
Chemical Name N-[[4-[(pyridin-2-ylamino)methyl]phenyl]methyl]pyridin-2-amine
Canonical SMILES C1=CC=NC(=C1)NCC2=CC=C(C=C2)CNC3=CC=CC=N3
Formula C18H18N4 M.Wt 290.36
Solubility Soluble in DMSO > 10 mM Storage Store at -20°C
Physical Appearance A crystalline solid Shipping Condition Evaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.

Background

WZ811 is a small molecule antagonist of CXC chemokine receptor 4 (CXCR4) [1].

WZ811 is synthesized with two aromatic amine moieties. It is found to effectively inhibit TN14003 binding to CXCR4 with EC50 value of 0.3nM at first. And then WZ811 is found to have ability in counteracting SDF-1 function and blocking CXCR4/SDF-1-mediated signaling. In the cAMP assay, WZ811 reduces the effect on cAMP caused by 150ng/ml SDF-1 significantly. It also blocks the SDF-1 induced Matrigel invasion with EC50 value of 5.2nM. Since CXCR4 is involved in the pathogeneses of a wide range of infectious, inflammatory and other diseases, WZ811 is developed for the treatment of various CXCR4-related diseases. It is reported to have weak anti-HIV activity in cell culture [1, 2].

References:
[1] Zhan W, Liang Z, Zhu A, et al. Discovery of small molecule CXCR4 antagonists. Journal of medicinal chemistry, 2007, 50(23): 5655-5664.
[2] Choi W T, Duggineni S, Xu Y, et al. Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4). Journal of medicinal chemistry, 2011, 55(3): 977-994.